Johns Hopkins Psychiatry Guide
Esketamine
INDICATIONS
FDA
FDA
- Treatment-resistant depression as monotherapy or adjunct to antidepressant therapy
- MDD with acute suicidal ideation as adjunct to antidepressant therapy
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 30, 2025
Citation
Qureshi, Imran. "Esketamine." Johns Hopkins Psychiatry Guide, The Johns Hopkins University, 2025. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787505/all/Esketamine.
Qureshi I. Esketamine. Johns Hopkins Psychiatry Guide. The Johns Hopkins University; 2025. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787505/all/Esketamine. Accessed October 29, 2025.
Qureshi, I. (2025). Esketamine. In Johns Hopkins Psychiatry Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787505/all/Esketamine
Qureshi I. Esketamine [Internet]. In: Johns Hopkins Psychiatry Guide. The Johns Hopkins University; 2025. [cited 2025 October 29]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787505/all/Esketamine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Esketamine
ID - 787505
A1 - Qureshi,Imran,PharmD, BCPP
Y1 - 2025/08/30/
BT - Johns Hopkins Psychiatry Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787505/all/Esketamine
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
